Our portfolio of microbial antigens includes native and recombinant antigens derived from bacterial, fungal, and parasitic species for research, assay development, and diagnostic applications. Available targets cover a broad range of clinically relevant pathogens such as Chlamydia, Borrelia, Toxoplasma, Mycoplasma, and many others. Native antigens are prepared from cultivated pathogens and purified antigen mixtures, while recombinant antigens are produced in expression systems such as E. coli or yeast for improved consistency and scalability.
Microbial antigens are widely used in ELISA, CLIA, immunoblot, and other immunoassay platforms for the detection of pathogen-specific antibodies or antigens. Depending on the application, they support sensitive and specific detection of IgG, IgM, or IgA responses in infectious disease research and assay development. Our antigen portfolio is designed to provide reliable performance, high batch consistency, and flexible integration into diagnostic workflows and OEM projects.
